Comparison of immunochemical and radioligand binding assays for estrogen receptors in human breast tumors

G. Di Fronzo, P. Miodini, M. Brivio, V. Cappelletti, D. Coradini, G. Granata, E. Ronchi

Research output: Contribution to journalArticle

Abstract

We have compared a new enzyme immunoassay (EIA) for estrogen receptors (ER) with our conventional radioligand binding assays (multipoint dextran-coated charcoal assay for cytoplasmic ER and hydroxylapatite exchange assay for nuclear ER). Cytoplasmic ERs were measured in 76 human breast cancer specimens by EIA and by five-point Scatchard analysis. The correlation between the two assays yielded a straight line with a slope of 0.92 (r = 0.95; P <0.001); conversely, in 31 nuclear salt extracts, linear regression analysis of hydroxylapatite exchange assay data with EIA showed a clear correlation (r = 0.93; P <0.001) but a slope of 1.7, demonstrating that EIA detects more ER sites. The binding of the antibody to the cytoplasmic ER molecules was investigated by sucrose density gradient analysis, which showed that EIA recognizes both cytoplasmic forms (9 and 3S), but does not distinguish between them. Advantages and drawbacks of this method are discussed with respect to its application for routine receptor determination for clinical management of breast cancer patients.

Original languageEnglish
JournalCancer Research
Volume46
Issue number8 SUPPL.
Publication statusPublished - 1986

Fingerprint

Radioligand Assay
Immunoenzyme Techniques
Estrogen Receptors
Breast Neoplasms
Durapatite
Cytoplasmic and Nuclear Receptors
Charcoal
Dextrans
Sucrose
Linear Models
Salts
Regression Analysis
Antibodies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Di Fronzo, G., Miodini, P., Brivio, M., Cappelletti, V., Coradini, D., Granata, G., & Ronchi, E. (1986). Comparison of immunochemical and radioligand binding assays for estrogen receptors in human breast tumors. Cancer Research, 46(8 SUPPL.).

Comparison of immunochemical and radioligand binding assays for estrogen receptors in human breast tumors. / Di Fronzo, G.; Miodini, P.; Brivio, M.; Cappelletti, V.; Coradini, D.; Granata, G.; Ronchi, E.

In: Cancer Research, Vol. 46, No. 8 SUPPL., 1986.

Research output: Contribution to journalArticle

Di Fronzo, G, Miodini, P, Brivio, M, Cappelletti, V, Coradini, D, Granata, G & Ronchi, E 1986, 'Comparison of immunochemical and radioligand binding assays for estrogen receptors in human breast tumors', Cancer Research, vol. 46, no. 8 SUPPL..
Di Fronzo, G. ; Miodini, P. ; Brivio, M. ; Cappelletti, V. ; Coradini, D. ; Granata, G. ; Ronchi, E. / Comparison of immunochemical and radioligand binding assays for estrogen receptors in human breast tumors. In: Cancer Research. 1986 ; Vol. 46, No. 8 SUPPL.
@article{2d80772a9fca414a9be6c3787f9dc132,
title = "Comparison of immunochemical and radioligand binding assays for estrogen receptors in human breast tumors",
abstract = "We have compared a new enzyme immunoassay (EIA) for estrogen receptors (ER) with our conventional radioligand binding assays (multipoint dextran-coated charcoal assay for cytoplasmic ER and hydroxylapatite exchange assay for nuclear ER). Cytoplasmic ERs were measured in 76 human breast cancer specimens by EIA and by five-point Scatchard analysis. The correlation between the two assays yielded a straight line with a slope of 0.92 (r = 0.95; P <0.001); conversely, in 31 nuclear salt extracts, linear regression analysis of hydroxylapatite exchange assay data with EIA showed a clear correlation (r = 0.93; P <0.001) but a slope of 1.7, demonstrating that EIA detects more ER sites. The binding of the antibody to the cytoplasmic ER molecules was investigated by sucrose density gradient analysis, which showed that EIA recognizes both cytoplasmic forms (9 and 3S), but does not distinguish between them. Advantages and drawbacks of this method are discussed with respect to its application for routine receptor determination for clinical management of breast cancer patients.",
author = "{Di Fronzo}, G. and P. Miodini and M. Brivio and V. Cappelletti and D. Coradini and G. Granata and E. Ronchi",
year = "1986",
language = "English",
volume = "46",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "8 SUPPL.",

}

TY - JOUR

T1 - Comparison of immunochemical and radioligand binding assays for estrogen receptors in human breast tumors

AU - Di Fronzo, G.

AU - Miodini, P.

AU - Brivio, M.

AU - Cappelletti, V.

AU - Coradini, D.

AU - Granata, G.

AU - Ronchi, E.

PY - 1986

Y1 - 1986

N2 - We have compared a new enzyme immunoassay (EIA) for estrogen receptors (ER) with our conventional radioligand binding assays (multipoint dextran-coated charcoal assay for cytoplasmic ER and hydroxylapatite exchange assay for nuclear ER). Cytoplasmic ERs were measured in 76 human breast cancer specimens by EIA and by five-point Scatchard analysis. The correlation between the two assays yielded a straight line with a slope of 0.92 (r = 0.95; P <0.001); conversely, in 31 nuclear salt extracts, linear regression analysis of hydroxylapatite exchange assay data with EIA showed a clear correlation (r = 0.93; P <0.001) but a slope of 1.7, demonstrating that EIA detects more ER sites. The binding of the antibody to the cytoplasmic ER molecules was investigated by sucrose density gradient analysis, which showed that EIA recognizes both cytoplasmic forms (9 and 3S), but does not distinguish between them. Advantages and drawbacks of this method are discussed with respect to its application for routine receptor determination for clinical management of breast cancer patients.

AB - We have compared a new enzyme immunoassay (EIA) for estrogen receptors (ER) with our conventional radioligand binding assays (multipoint dextran-coated charcoal assay for cytoplasmic ER and hydroxylapatite exchange assay for nuclear ER). Cytoplasmic ERs were measured in 76 human breast cancer specimens by EIA and by five-point Scatchard analysis. The correlation between the two assays yielded a straight line with a slope of 0.92 (r = 0.95; P <0.001); conversely, in 31 nuclear salt extracts, linear regression analysis of hydroxylapatite exchange assay data with EIA showed a clear correlation (r = 0.93; P <0.001) but a slope of 1.7, demonstrating that EIA detects more ER sites. The binding of the antibody to the cytoplasmic ER molecules was investigated by sucrose density gradient analysis, which showed that EIA recognizes both cytoplasmic forms (9 and 3S), but does not distinguish between them. Advantages and drawbacks of this method are discussed with respect to its application for routine receptor determination for clinical management of breast cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=0022474143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022474143&partnerID=8YFLogxK

M3 - Article

C2 - 3524809

AN - SCOPUS:0022474143

VL - 46

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 8 SUPPL.

ER -